1. Home
  2. DIAX vs RIGL Comparison

DIAX vs RIGL Comparison

Compare DIAX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DIAX
  • RIGL
  • Stock Information
  • Founded
  • DIAX 2005
  • RIGL 1996
  • Country
  • DIAX United States
  • RIGL United States
  • Employees
  • DIAX N/A
  • RIGL N/A
  • Industry
  • DIAX Finance Companies
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • DIAX Finance
  • RIGL Health Care
  • Exchange
  • DIAX Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • DIAX 535.3M
  • RIGL 537.6M
  • IPO Year
  • DIAX N/A
  • RIGL 2000
  • Fundamental
  • Price
  • DIAX $14.81
  • RIGL $35.28
  • Analyst Decision
  • DIAX
  • RIGL Buy
  • Analyst Count
  • DIAX 0
  • RIGL 6
  • Target Price
  • DIAX N/A
  • RIGL $39.83
  • AVG Volume (30 Days)
  • DIAX 96.6K
  • RIGL 543.2K
  • Earning Date
  • DIAX 01-01-0001
  • RIGL 11-04-2025
  • Dividend Yield
  • DIAX 7.93%
  • RIGL N/A
  • EPS Growth
  • DIAX N/A
  • RIGL 2698.26
  • EPS
  • DIAX N/A
  • RIGL 6.20
  • Revenue
  • DIAX N/A
  • RIGL $282,076,000.00
  • Revenue This Year
  • DIAX N/A
  • RIGL $59.93
  • Revenue Next Year
  • DIAX N/A
  • RIGL N/A
  • P/E Ratio
  • DIAX N/A
  • RIGL $5.68
  • Revenue Growth
  • DIAX N/A
  • RIGL 79.13
  • 52 Week Low
  • DIAX $12.80
  • RIGL $14.63
  • 52 Week High
  • DIAX $15.12
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • DIAX 52.18
  • RIGL 60.36
  • Support Level
  • DIAX $14.73
  • RIGL $28.08
  • Resistance Level
  • DIAX $14.94
  • RIGL $39.56
  • Average True Range (ATR)
  • DIAX 0.14
  • RIGL 1.97
  • MACD
  • DIAX -0.00
  • RIGL 0.89
  • Stochastic Oscillator
  • DIAX 50.52
  • RIGL 62.66

About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: